Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETHINC: Indacaterol/Glycopyrrolate in Early COPD
NCT02867761Phase 3Completed
- Sponsor
- University of Michigan
- Start
- Aug 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol, glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by University of Michigan. Started Aug 2017; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02867761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867761.